SM
ITCI

Sciencast Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Sciencast Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,306
Closed -$276K – 458
2023
Q3 		$276K Buy
+5,306
New +$309K 0.13% 247

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sciencast Management's ITCI Position: Q4 2023 in Review

Sciencast Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2023, closing a stake of 5,306 shares — an estimated $276K sold.

Sciencast Management first reported a position in ITCI in Q3 2023 and held it in 1 quarter. The position peaked at $276K in Q3 2023. 333 funds tracked by Wall St. Rank hold ITCI as of Q4 2023.

  • Sciencast Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2023 after selling out during the quarter.
  • Sciencast Management sold 5,306 Intra-Cellular Therapies Inc. shares in Q4 2023, an estimated $276K.
  • Sciencast Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2023 and held it in 1 quarter.
  • Sciencast Management's Intra-Cellular Therapies Inc. position peaked at $276K in Q3 2023.
  • 333 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2023.

Based on Sciencast Management's 13F filing for Q4 2023, filed 14 Feb 2024.